Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Sacituzumab Govitecan Plus Pembrolizumab in Resectable NSCLC
NCT06055465Phase 2Active, not recruiting
- Sponsor
- The Chinese University of Hong Kong
- Start
- Feb 2024
- Primary completion
- Dec 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sacituzumab govitecan in non-small cell lung cancer (NSCLC), sponsored by The Chinese University of Hong Kong. Primary endpoint: Pathological Complete Response Rate at 2 years. Started Feb 2024; status: active, not recruiting.
02
Drugs
sacituzumab govitecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06055465.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06055465.